Merck & Schering-Plough Merger Presentation. September 14, 2009
|
|
- Lydia Hensley
- 5 years ago
- Views:
Transcription
1 Merck & Schering-Plough Merger Presentation September 14, 2009
2 Forward-Looking Statements Forward-Looking Statements This communication includes forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of Such statements may include, but are not limited to, statements about the benefits of the proposed merger between Merck and Schering-Plough, including future financial and operating results, the combined company s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck s and Schering-Plough s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the proposed merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the ability to obtain governmental and self-regulatory organization approvals of the merger on the proposed terms and schedule; the actual terms of the financing required for the merger and/or the failure to obtain such financing; the failure of Schering-Plough or Merck stockholders to approve the merger; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; the possibility that the merger does not close, including, but not limited to, due to the failure to satisfy the closing conditions; Merck s and Schering-Plough s ability to accurately predict future market conditions; dependence on the effectiveness of Merck s and Schering-Plough s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. Merck and Schering-Plough undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck s 2008 Annual Report on Form 10-K, Schering- Plough s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009, the proxy statement filed by Merck on June 25, 2009 and each company s other filings with the Securities and Exchange Commission (the SEC ) available at the SEC s Internet site ( These reports are available on our websites at and 2
3 Transaction Overview Merger of Merck and Schering-Plough Price per Schering-Plough Share: $10.50 cash and of a share of the combined company (fixed exchange ratio); total consideration $41.1 billion Total value of $23.61 per Schering-Plough share based on Merck s closing stock price on March 6, 2009 Premium: 34% to Schering-Plough shareholders based on Schering-Plough s closing stock price on March 6, 2009 Ownership: Schering-Plough shareholders to own approximately 32% and Merck shareholders to own approximately 68% of the combined company Anticipated Closing: Fourth quarter of 2009, subject to regulatory approvals Transaction Structure: Reverse Merger Schering-Plough will be renamed Merck and will continue as surviving public corporation Each Merck share will automatically become a share of the combined company 3
4 Merck and Schering-Plough: A Compelling Combination A Formula for Growth Strong, complementary portfolio: Broadens scope of Merck commercial portfolio with leading franchises in key therapeutic areas Schering-Plough products provide long-lived marketing exclusivity Enhances R&D efforts and pipeline: Adds high potential early-, mid- and late-stage pipeline candidates to provide platform for sustainable growth Expanded global presence: Dramatically accelerates Merck's international growth efforts, especially in key emerging markets Substantial synergies: Incremental $3.5 billion in annual cost savings expected beyond 2011 Financial Strength Maintain Merck dividend: Based on strong free cash flow generated by combination Maintain strong balance sheet: Merck has maintained its credit ratings Transaction Designed to Maximize Total Shareholder Returns 4
5 Broadens and Complements Commercial Portfolio with Leading Franchises Therapeutic Area Schering-Plough Products Merck Products Cardio / Metabolic Infectious Disease Respiratory Women s Health Arthritis / Immunology Oncology 5
6 Value Creating Consolidation of Cholesterol JV Merck/Schering-Plough cholesterol JV generated revenue of $4.6 billion in 2008 Merck s 100% ownership enables: Streamlined decision-making ability Opportunity for leveraging cholesterol franchise through future combinations with ZETIA 6
7 REMICADE and Golimumab REMICADE is a well-established biologic product for inflammatory / immunological diseases Marketed by Schering-Plough in international territories, marketed by Johnson & Johnson in U.S. Schering-Plough s 2008 sales were $2.1bn Golimumab is a late-stage pipeline product expected to be launched in 2009 under the brand name SIMPONI Recently approved by the FDA Subject to profit-sharing arrangement with Johnson & Johnson, with Schering-Plough share decreasing from 60% to 50% over next five years. In addition, Schering-Plough incurs additional direct cost including Direct Selling, Promotion and R&D Johnson & Johnson has commenced an arbitration, we believe distribution rights to REMICADE and Golimumab will be retained 7
8 Animal Health and Consumer Health Businesses Animal Health Intervet/Schering-Plough Animal Health is a global leader in animal health, with market-leading products for a broad range of species More than 1,000 marketed products balanced between vaccines and pharmaceuticals Consumer Health Successful Rx-to-OTC switch company Leading consumer brands including CLARITIN, COPPERTONE and DR. SCHOLL S More than 12 new introductions planned in
9 Strength Across Key Therapeutic Areas Combined 2008 Sales 1 : $46.9B Other 18% Cardio/ Metabolic 24% OTC 3% Animal Health 6% Oncology 3% Arthritis/ Immunology 6% Respiratory 14% Women's Health 8% Infectious Disease 9% Vaccines 9% 1 Sales figures reflect Merck and Schering-Plough reported 2008 sales plus 100% of MSP JV reported sales 9
10 More Geographically Diverse Revenue Base Merck: 2008 $23.9B Combined ¹: 2008 $46.9B Asia Pacific 6% Latin America 4% Japan 8% Latin America Asia 7% Pacific 5% Japan 6% Europe and Canada 26% United States 56% Europe and Canada 35% United States 47% International Sales $10.5 billion International Sales $25.0 billion 1 Sales figures reflect Merck and Schering-Plough reported 2008 sales plus 100% of MSP JV reported sales 10
11 Merck and Schering-Plough Products Provide Long-Remaining Marketing Exclusivity Long periods of expected marketing exclusivity COZAAR/HYZAAR EU U.S. CLARINEX SINGULAIR EU U.S. / EU REMICADE EU TEMODAR EU U.S. JPN NASONEX EU U.S. ZETIA VYTORIN PEG-INTRON U.S. / EU U.S. U.S. / JPN JPN EU EU JANUVIA/JANUMET U.S. ISENTRESS GARDASIL U.S. U.S Merck MSP JV 11
12 Shared Commitment to Discovering and Developing Important Therapies for Patients Schering-Plough and Merck R&D organizations share a common culture of scientific excellence Schering-Plough has an established presence in oncology and neuroscience, two areas Merck is building Schering-Plough s expertise in novel biologics complements Merck s BioVentures technology Schering-Plough s therapeutic areas of focus complement those of Merck Mechanistic diversity adds strength to our joint pipeline 12
13 Mid- and Late-Stage Pipeline: A Powerful Combination Select Programs Current as of July 2009 (1) Cardiovascular/ Metabolic Infectious Disease Respiratory & Immunology Neuroscience Oncology Endocrine & Women s Health * Merck MK-0859 (atherosclerosis) MK-0524A & MK-0524B MK-6221 (vernakalant) ISENTRESS Tx Naïve (HIV) ISENTRESS QD (HIV) MK-7009 (HCV) MK-0476C (asthma) MK-0633 (COPD) MK-0974 (migraine) MK-4305 (insomnia) MK-8669 (sarcoma) MK-0646 (colorectal cancer) MK-0822 (osteoporosis) V-503 (HPV Vaccine) GARDASIL (27-45 years) = under regulatory review * = recent approval 13 * * Schering-Plough TRA (ACS, 2 prevention) Acadesine (reperfusion injury) Vicriviroc (HIV) Boceprevir (HCV) SIMPONI (inflammation) MFF (Asthma) Allergy Immunotherapy Tablet 1) Source: Merck from 10-Q filed on August 3, 2009; Schering-Plough from website July 2009 SAPHRIS (schiz.; bipolar) Sugammadex (anesthesia) Preladenant (Parkinson s) PEGINTRON (melanoma) TEMODAR I.V. (cancer) IGF-1R (colorectal cancer) Corifollitropin alfa (fertility) Esmirtazapine (hot flashes) NOMAC/E2 (contraceptive) International rights only MFF = Mometasone/Formoterol
14 Broader and Deeper Clinical Pipeline Current as of July 2009 (1) Alzheimer s Disease, MK-0249 Anemia, MK-2578 Atherosclerosis, MK-1903 Cancer, MK-0646 Cardiovascular, MK-0736 Cardiovascular, MK (vernakalant [oral]) Diabetes, MK-0893 Diabetes, MK-0941 Diabetes, MK-8245 Infectious Disease, MK-3415A Infectious Disease, MK-7009 Infectious Disease, V419 Infectious Disease, V710 Insomnia, MK-4305 Osteoporosis, MK-5442 Psychiatric Disease, MK-0594 Psychiatric Disease, MK-5757 Psychiatric Disease, MK-8998 Respiratory Disease, MK-0476C Respiratory Disease, MK-0633 Sarcopenia, MK-2866 (ostarine) Phase Phase II II Compounds Compounds ADHD & Depression, AMPA PAM Alcohol Dependence & Schizophrenia, Glycine Uptake Inh. Allergic Rhinitis, Mometasone/Oxymetazoline Cancer, CDK Inhibitor Cancer, CHK-1 Inhibitor 14 Athero., MK-0524A Athero., MK-0524B Athero., MK-0859 (anacetrapib) Cancer, MK-8669 (ridaforolimus) Diabetes, MK-0431C (Januvia / pioglitazone) Cancer, Robatumumab + + Common Cold and Asthma Exacerbations, Pleconaril COPD, CXCR2 Receptor Antagonist Dust Mite Allergies, Allergy Immunotherapy Tablet 3 Emesis, Rolapitant Hepatitis C, Protease Inhibitor (SCH ) Parkinson s, Preladenant Onychomycosis, Topical Antifungal Ragweed Allergies, Allergy Immunotherapy Tablet 2 Merck HPV Vaccine, V503 Migraine, MK-0974 (telcagepant) Ophthalmology, MK-2452 (tafluprost) Osteoporosis, MK-0822 (odanacatib) Schering-Plough Phase Phase III III Compounds Compounds Acute Coronary Syndrome, TRA COPD, Mometasone/Formoterol Contraception, NOMAC/E2 Grass Pollen Allergies, Allergy Immunotherapy Tablet Hepatitis C, Boceprevir HIV, Vicriviroc Hot Flashes, Esmirtazapine Reperfusion Injury, Acadesine 1) Source: Merck from 10-Q filed on August 3, 2009; Schering-Plough from website July ) An affiliate of the Company has exclusive rights outside of the United States, Canada and Mexico to vernakalant (IV) for rapid conversion of acute atrial fibrillation to normal heart rhythm. On July 26, 2009, the Company submitted a Marketing Authorization Application to the European Medicines Agency seeking marketing approval for vernakalant (IV) in the EU. 3) North American rights only
15 Significant Financial Benefits Significant Accretion: Anticipated to be modestly accretive to non-gaap EPS in first year following the close and significantly accretive thereafter Synergies: Significant cost savings opportunities of incremental ~$3.5bn annually beyond 2011 Investment: Enhance financial flexibility to invest in promising drug candidates as well as external R&D Maintains Merck s Strong Financial Profile Near-Term Tax Rate: Anticipate no change 2013 Cash Flow: $15 billion free cash flow generated by combination Dividend: No change to Merck dividend Credit Rating: Transaction structured to maintain current credit ratings 15
16 Application of Merck s Plan to Win Across a Broader Platform Provides Opportunity for Margin Improvement Plan to leverage best practices at Merck Application of Merck s Plan to Win across a broader platform Consolidation of VYTORIN/ZETIA Cholesterol JV Consistent therapeutic category focus provides opportunities for consolidation in both sales and marketing and R&D Pretax Margins 1 Merck standalone 2008 Combined 2 unsynergized 2013 Combined 2 synergized % 37% 40% ¹ Pretax Margins exclude certain items: restructuring costs, purchase accounting adjustments, acquisition-related costs and certain other significant items 2 Assumes contribution from Animal Health business is reflected in Equity Income 16
17 Significant Cost Savings Opportunities Annual cost savings expected to be achieved beyond 2011 $950 million Merck 2008 program $1.50 billion Schering-Plough PTP initiative $3.50 billion $5.95 billion Transaction related incremental cost savings Combined annual cost savings beyond Annual incremental synergies of ~$3.5 billion beyond 2011 Approximately half of annual synergies achieved in first full year following transaction Approximately 75% in second full year Incremental synergies broken down as follows: Marketing & Admin.: ~60% Manufacturing/R&D: ~40% Cost savings are incremental to ongoing initiatives at both companies Merck 2008 Program Schering-Plough PTP Initiative
18 Merger Financing Anticipated Interest Rates 4-5% $8.5 billion Needed Actual Average Rate = 4% $9.55 billion Available Merial Proceeds, $2.8 Asset Sale, $3 Revolving, $2.5 Revolving, $2.5 Notes 2039, $0.75 Bridge Loan, $3 Notes 2019, $1.25 Notes 2015, $1 $4.25 billion Bonds Notes 2011, $1.25 March 9th 18 Current
19 Integration Process Merck s integration team to be led by Adam Schechter, President, Global Pharmaceuticals Schering-Plough s integration team to be led by Brent Saunders, senior vice president and president, Consumer Health Care Similar culture and established working relationship will facilitate smooth transition Company to be called Merck; headquartered in Whitehouse Station, New Jersey 19
20 Diversified Portfolio to Drive Growth Human Health Animal Health Consumer Health Care EUCan I EUCan II Japan United States Emerging Markets Cardiovascular Diabetes/ Obesity Biologics Focused Growth Areas Integrated: Commercial Oncology Neurosciences/ Ophthalmology Vaccines R&D Manufacturing Bone/Respiratory Immunology/ Dermatology Infectious Disease Mature Brands Women s Health/ Endocrine 20
21 Executive Committee Chairman, President & Chief Executive Officer Global Human Health Merck Research Laboratories Merck Manufacturing Division Finance Human Resources Legal/Global Policy/ Global Comm. Global Services Corporate Strategy Consumer Health Care Animal Health Chief Compliance Officer Chief Medical Officer 21
22 Roadmap to Completion Shareholder vote August 7 th Shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough Integration focused on key success factors to achieve New Merck potential Maintaining momentum in the current business and the late stage pipeline Launching the new combined company in a way that ensures a smooth transition for our customers Launching new products exceptionally well Capturing both revenue growth and cost savings opportunities Ensuring we have the right people in the right jobs in the right culture Complete all necessary regulatory approvals Transaction expected to be completed in the fourth quarter of
23 Merck and Schering-Plough: A Compelling Combination A Formula for Growth Strong, complementary portfolio: Broadens scope of Merck commercial portfolio with leading franchises in key therapeutic areas Schering-Plough products provide long-lived marketing exclusivity Enhances R&D efforts and pipeline: Adds high potential early-, mid- and late-stage pipeline candidates to provide platform for sustainable growth Expanded global presence: Dramatically accelerates Merck's international growth efforts, especially in key emerging markets Substantial synergies: Incremental $3.5 billion in annual cost savings expected beyond 2011 Financial Strength Maintain Merck dividend: Based on strong free cash flow generated by combination Maintain strong balance sheet: Merck has maintained its credit ratings Transaction Designed to Maximize Total Shareholder Returns 23
24 Merck & Schering-Plough Merger
New Merck Pipeline. Combined Legacy Merck and Schering-Plough Research Pipelines
New Merck Pipeline Combined Legacy Merck and Schering-Plough Research Pipelines November 4, 2009 Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined
More informationMerck Pipeline. April 30, 2010
Merck Pipeline April 30, 2010 Forward-looking statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation
More informationMerck Pipeline. October 15, 2009
Merck Pipeline October 15, 2009 2 Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationMerck Pipeline. As of August 3, 2015
Merck Pipeline As of August 3, 2015 Merck Pipeline as of August 3, 2015 Phase 2 Phase 2 Phase 3 Phase 3 Phase 3 Alzheimer s Disease MK-7622 Contraception, Next Generation Ring MK-8342B Allergy, House Dust
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationJefferies Global Life Sciences Conference June 2010
Jefferies Global Life Sciences Conference June 2010 Cautionary Statement This presentation contains "forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationFOR IMMEDIATE RELEASE Media Contact: Lainie Keller Investor Contacts: Teri Loxam (908) (908) Amy Klug (908)
News Release FOR IMMEDIATE RELEASE Media Contact: Lainie Keller Investor Contacts: Teri Loxam (908) 236-5036 (908) 740-1986 Amy Klug (908) 740-1898 Merck Announces Third-Quarter 2016 Financial Results
More informationSG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc
SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationMerck Pipeline. November 1, 2017
Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationAstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.
[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationMEDICAL CANNABIS COMPANY
MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationAnnual Meeting of Stockholders. April 26, 2005
Annual Meeting of Stockholders April 26, 2005 Research Update Peter S. Kim President, Merck Research Laboratories April 26, 2005 Forward-Looking Statements This presentation contains "forward-looking statements"
More informationMerck & Co., Inc. Adam H. Schechter Executive Vice President and President Global Human Health. Jefferies Global Healthcare Conference
Adam H. Schechter Executive Vice President and President Global Human Health Merck & Co., Inc. Jefferies Global Healthcare Conference November 20, 2014 Forward-Looking Statement This presentation includes
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationMerck Pipeline. August 1, 2018
Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationJP Morgan 2011 Healthcare Conference. David Redfern, Chief Strategy Officer 12 January 2011
JP Morgan 2011 Healthcare Conference David Redfern, Chief Strategy Officer 12 January 2011 GSK performance through patent cliff + Avandia GSK patent cliff + Avandia 2006-2009 US turnover for se elected
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationNomura Healthcare Conference
Nomura Healthcare Conference Sebastien Martel Head of Investor Relations London, July 1st, 2011 Forward Looking Statements 2 This presentation contains forward-looking statements as defined in the Private
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationSucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference
Sucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference June 3, 2015 Peter Greenleaf Chief Executive Officer Forward-Looking Statements This presentation contains "forward-looking statements"
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationInvestor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications
Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationClick Here to Watch Video
Click Here to Watch Video Live the Legacy. Live the Legacy. Protect the Future. Mike Nally, President, Global Vaccines December, 2017 This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationInvestor Presentation. Q May 21, 2018
Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationVICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06
VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationBeyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective
Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective IAIM Regional Meeting for the Americas and Europe 1 February 2017 Anupama Tantri
More informationLeading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products
ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationFull Year and Fourth Quarter Results ended 31 December Shire Pharmaceuticals Group plc
Full Year and Fourth Quarter Results ended 31 December 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationRULES OF CONDUCT OF INSIDERS RESPECTING
T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationReynolds American to Acquire Lorillard
Reynolds American to Acquire Lorillard The Next Step in Transforming Tobacco July 15, 2014 Forward Looking Statements This presentation contains forward-looking information. Future results or events can
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationDuPont Nutrition & Health Craig Binetti, President
Craig Binetti, President Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this
More information